Literature DB >> 2214607

Tumor necrosis factor: an update on basic research and clinical applications.

M Schleuning1, R Munker.   

Abstract

Tumor necrosis factor is one of the recently cloned cytokines with pleiotropic effects on normal and malignant cells. Our knowledge about the scope of cells producing or responding to this cytokine has enormously expanded. In critically ill patients with acute hepatic failure, acute graft-versus-host disease, or septic shock, circulating tumor necrosis factor can be measured and useful prognostic correlations do exist. Despite promising in vitro results, early clinical trials with tumor necrosis factor for the treatment of cancer have failed thus far to reveal major antineoplastic activity in cancer patients. However, more clinical trials are necessary, since different routes of administration and combinations with other cytokines may lead to favorable results.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2214607     DOI: 10.1007/bf01662779

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  90 in total

1.  Tumour necrosis factor and lymphotoxin genes map close to H-2D in the mouse major histocompatibility complex.

Authors:  U Müller; C V Jongeneel; S A Nedospasov; K F Lindahl; M Steinmetz
Journal:  Nature       Date:  1987 Jan 15-21       Impact factor: 49.962

Review 2.  Cachectin: more than a tumor necrosis factor.

Authors:  B Beutler; A Cerami
Journal:  N Engl J Med       Date:  1987-02-12       Impact factor: 91.245

3.  Intralesional application of recombinant human tumor necrosis factor alpha induces local tumor regression in patients with advanced malignancies.

Authors:  H H Bartsch; K Pfizenmaier; M Schroeder; G A Nagel
Journal:  Eur J Cancer Clin Oncol       Date:  1989-02

4.  Natural killer-sensitive targets stimulate production of TNF-alpha but not TNF-beta (lymphotoxin) by highly purified human peripheral blood large granular lymphocytes.

Authors:  P M Peters; J R Ortaldo; M R Shalaby; L P Svedersky; G E Nedwin; T S Bringman; P E Hass; B B Aggarwal; R B Herberman; D V Goeddel
Journal:  J Immunol       Date:  1986-10-15       Impact factor: 5.422

5.  Tumor necrosis factor can induce both apoptic and necrotic forms of cell lysis.

Authors:  S M Laster; J G Wood; L R Gooding
Journal:  J Immunol       Date:  1988-10-15       Impact factor: 5.422

6.  Immunoregulation and production of tumor necrosis factor alpha by human thymocytes.

Authors:  G H Reem; A Duggan; M Schleuning
Journal:  Cancer Res       Date:  1989-07-01       Impact factor: 12.701

7.  Gamma interferon enhances macrophage transcription of the tumor necrosis factor/cachectin, interleukin 1, and urokinase genes, which are controlled by short-lived repressors.

Authors:  M A Collart; D Belin; J D Vassalli; S de Kossodo; P Vassalli
Journal:  J Exp Med       Date:  1986-12-01       Impact factor: 14.307

8.  Monocyte-conditioned medium, interleukin-1, and tumor necrosis factor stimulate the acute phase response in human hepatoma cells in vitro.

Authors:  G J Darlington; D R Wilson; L B Lachman
Journal:  J Cell Biol       Date:  1986-09       Impact factor: 10.539

9.  Effect of tumor necrosis factor alpha on mitogen-activated human B cells.

Authors:  J H Kehrl; A Miller; A S Fauci
Journal:  J Exp Med       Date:  1987-09-01       Impact factor: 14.307

10.  Cachectin/tumor necrosis factor mediates changes of skeletal muscle plasma membrane potential.

Authors:  K J Tracey; S F Lowry; B Beutler; A Cerami; J D Albert; G T Shires
Journal:  J Exp Med       Date:  1986-10-01       Impact factor: 14.307

View more
  2 in total

1.  TNF induces cytoplasmic vesicles in actinomycin D-treated K 562 cells.

Authors:  R Munker; L Greither; M Darsow; S Pander; W Wilmanns
Journal:  Ann Hematol       Date:  1992-07       Impact factor: 3.673

2.  Cellular and cytokine responses of the human central nervous system to intracranial administration of tumor necrosis factor alpha for the treatment of malignant gliomas.

Authors:  M Tada; Y Sawamura; S Sakuma; K Suzuki; H Ohta; T Aida; H Abe
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.